Amgen Inc.
AMGN
#75
Rank
$238.062 B
Marketcap
United States
Country
$440.34
Share price
6.29%
Change (1 day)
36.44%
Change (1 year)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis;…
Key Metrics
Trailing P/E
23.37
Forward P/E
15.56
EPS (TTM)
$16.25
Forward EPS
$24.40
Price / Book
17.57
EV / EBITDA
14.4x
Beta
0.43
Dividend Yield
2.68%
Return on Equity
91.47%
Return on Assets
8.67%
Debt / Equity
490.28
Current Ratio
1.37
Gross Margin
71.89%
Operating Margin
35.55%
Net Profit Margin
22.95%
Free Cash Flow
$8.646B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 16
-14.92%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$36.751B
Latest Net Income$7.711B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Amgen Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
AMGN
No recent news available. Set FINNHUB_API_KEY to enable news.
